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Non-covalent polymer-protein conjugation is emerging as a potential route to improve pharmacokinetics and 
pharmacodynamics of protein therapeutics. In this study, a family of structurally related block copolymers of 
mPEG2k - poly(glutamic acid) with linear A-B (mPEG2k-lin-polyGA) and miktoarm A-B3 ((mPEG2k-mik-(polyGA)3) 
structure was synthesised by N-carboxyanhydride (NCA) ring-opening polymerisation to assess the effect of 
macromolecular topology of the copolymers on polymer-protein complexation. The data illustrate that the 
synthesised copolymers are capable of complexing a model protein, lysozyme, at optimal pH conditions through 
non-covalent interactions, with complexation efficiencies depending on the copolymers composition and molecular 
architecture. In native gel electrophoresis experiments, l inear mPEG2k-lin-GA10 copolymer, possessing a short 
polyanionic polyGA block, shows a low level of complexation, which does not change when the number of polyGA 
branches of the same size is increased, using a miktoarm mPEG2k-mik-(GA10)3 copolymer. However, enhanced 
complexation is observed when the same number of ionisable GA units (30) are displayed on a linear 
macromolecular scaffold; mPEG2k-mik-(GA10)3 vs. mPEG2k-lin-GA30. Again complexation efficiency did not increase 
when the number of complexing polyGA branches were increased; mPEG2k-lin-GA30 vs. mPEG2k-mik-(GA30)3. 
Nanoparticle tracking analysis (NTA) showed that the copolymer-protein complexes possessed hydrodynamic 
diameters in the 50-200 nm range, suggesting a degree of control in the assembly process. Sequestration of 
lysozyme within polymer complexes resulted in a decrease in its apparent enzymatic activity, which was re-
established on the complexes dissociation upon a treatment with competitive complexant. Intrinsic fluorescence 
and circular dichroism (CD) studies suggested structural conformation of the protein was not altered following 
complexation with mPEG2k-polyGA copolymers. Taken together, these results provide an initial structure-function 
relationship for protein-complexing mPEG2k-polyGA copolymers with variable macromolecular topology, opening 
the way for their future application in biological and biomedical studies.  
 
Introduction 
 
The global market of biotech drug sales has experienced an important growth over the past few decades and is 
expected to reach 445 billion of dollars by 2019.1 In particular recent advances in biotechnology, genetic engineering 
and molecular biology have resulted in a range of potential protein therapeutics which could address different unmet 
medical needs. However, effective protein delivery to the desired bodily target can be very challenging, due to 
potential immunogenicity,2 poor stability3 and often inefficient permeation of proteins through biological 
membranes. Nanomedicines, especially polymer-based nanosystems, are emerging as a potential strategy to 
overcome these therapeutic challenges. Bioconjugates, where a synthetic polymer, typically polyethyleneglycol 
(PEG), is covalently linked to a protein or peptide therapeutic, are one successful example of such an approach. 
PEGylation can increase the protein/peptide half-life by reducing its immunogenicity and plasma stability, and by 
decreasing the rate of its renal glomerular filtration.4, 5 This has resulted in a number of PEGylated protein and peptide 
therapeutics being available on the market.6 However, covalent polymer conjugation is not suitable for all proteins as 
it can potentially decrease their therapeutic efficacy due to irreversible modification or steric shielding of protein 
active site7 and does not answer all the challenges in protein-peptide delivery. Within this context, non-covalent 
protein–polymer formulations are emerging as potentially suitable alternatives. Recent examples include the work 
by the Salmaso and Caliceti’s group,  where a family of PEGs bearing a terminal cholanic moiety (mPEG5kDa-cholane) 
were utilised to generate polymer conjugates through non-covalent hydrophobic interactions with a range of protein 
and peptides, including recombinant human granulocyte colony stimulating factor (rh-G-CSF),8 palmytoilated 
vasoactive intestinal peptide (VIP),9 and recombinant human growth hormone (rh-GH).10 Crowley and co-workers 
have recently exploited specific carbohydrate-lectin recognition to design a α-L-fucose-terminated PEG able to 
reversibly PEGylate RSL trimer lectin.11 The intrinsically reversible nature of these interactions can allow complex 
disassembly under specific conditions - e.g. those found in the proximity of the intended biological target - which can 
offer therapeutic advantages. Additionally, these complexes can be assembled by simply mixing protein and polymer 
components under appropriate conditions, avoiding the often complex conjugation chemistries required for covalent 
PEGylation.   
Complexes assembled through ionic protein-polymer interactions are a particularly attractive class of protein 
conjugates. Stable complexes in nanometre size range have been assembled from PEG-polyanion/polycation 
copolymers and charged macromolecules including proteins12 and DNA.13 Nanocomplexes with average diameter of 
around 50 nm were produced from lysozyme and PEG-b-poly(aspartic acid)12 or insulin and oligolysine or 
oligoarginine-type homopeptide functionalised with PEG.14 These nanocomplexes are typically assembled using linear 
(co)polymers,14-16 whilst the use of macromolecules with more complex topologies such as dendrimer,17 graft18 or 
miktoarm19 structures, all of which could provide unique protein binding modalities, has been largely unexplored. 
In the present study we developed a family of mPEG2k-poly(glutamic acid) copolymers with either linear A-B, or 
miktoarm A-B3 structure, where the polyanion poly(glutamic acid) arm(s) are designed to provide ionic complexation 
with model protein lysozyme, whilst the PEG2k block infer steric stabilisation and minimises, or ideally, prevents 
secondary aggregation of the complexes.12  Poly(glutamic acid) is a widely investigated polymer20, 21, and was chosen 
in this study because of its low toxicity – e.g. it has been used as a macromolecular carrier in poly(GA)-paclitaxel 
conjugates that are being investigated in clinical trials for the treatment of a range of malignancies, including 
esophageal,22, 23 ovarian,24, 25 non-small-cell lung cancer,26-29 and glioblastoma multiforme – and the presence of 
multiple ionisable carboxylic acid group groups along its polymer chain which potentially could allow complexation of 
proteins presenting positively charged surface residues. 
Miktoarm star polymers - often simply referred to as miktoarm polymers - are star-shaped polymers where two or 
more macromolecular arms differ for their chemical composition, size, or both.19, 30, 31 The growing interest in 
miktoarm polymers comes from the possibility to incorporate both a variable number of polymer arms, and a plethora 
of chemical functionalities within one single macromolecule.31  Studies have specifically focussed on the differences 
in self-assembly modalities of amphiphilic miktoarm copolymers compared to their linear analogues.32, 33 
The use of miktoarm polymers to engineer drug deliver vectors and formulations is still in its infancy, with known 
examples being limited to micellar and polymersomal nanovectors.34-37 Bae and co-workers synthesised a library of 
Y-shaped AB2 copolymers incorporating one PEG chain and two PLGA arms, which could be assembled into 33-75 nm 
polymersomes, and which could encapsulate doxorubicin hydrochloride and released it in a controlled fashion.37 
Importantly, due to their macromolecular structure these miktoarm copolymers could form polymersomes in a much 
broader range of PEG volume fractions (0.2−0.7) than their linear diblock counterparts (0.2−0.4).   
In this work, A-B3 (mPEG-mik-(polyGA)3) miktoarm polymers were investigated along with their linear A-B mPEG-lin-
(polyGA) analogues for their ability to form nanocomplexes with egg white lysozyme model protein, with the aim of 
identifying a structure-function relationship for this novel linear and miktoarm family of complexing copolymers.   
Experimental 
3,4,5-tris(allyloxy)benzoic acid methyl ester (1). Methyl 3,4,5-trihydroxybenzoate (4.5 g, 25 mmol, 1.0 eq.) and K2CO3 
(16.4 g, 119 mmol, 4.8 eq.), were added to a round bottomed flask. Anhydrous acetonitrile (125 mL) and allyl bromide 
(21.0 g, 174 mmol, 7.0 eq.) were then added to the mixture under N2 atmosphere via syringe. The mixture was then 
heated to reflux and stirred whilst protected from the light. After 3 hours 1H Nuclear Magnetic Resonance (NMR) 
showed completed conversion of the aromatic alcohol functionalities into their corresponding allyl ethers. Volatiles 
were then removed under reduced pressure. Toluene (200 mL) was added to the resulting residue, and the insoluble 
salts were filtered off and washed with additional portions of toluene (3x100 mL). The toluene fractions were 
combined, and the solvent removed under pressure to give the desired product (1) as an oil which was used for the 
next step without further purification. Yield 7.5 g, quant. 1H NMR (400 MHz, CDCl3, δ, ppm): 7.28 (s, 2H, CHaromatic), 
6.14-6.01 (m, 3Hallyl), 5.47-5.16 (m, 6Hallyl), 4.65-4.59 (m, 6H, OCH2), 3.88 (s, 3H, CH3O). 13C NMR (101 MHz, CDCl3, δ, 
ppm): 166.7, 152.4, 142.0, 134.3, 133.1, 125.1, 118.0, 117.8, 108.9, 74.2, 70.0, 52.3. ESI-TOF mass spectrometry: 
expected m/z [M-H+] theor. 305.13, found 305.12. FT-IR: 1715 cm-1 C=O). 
3,4,5-tris(allyloxy)benzoic acid (2). To a solution of ester (1) (7.5 g, 25 mmol) in CH2Cl2/MeOH (9:1 v/v, 20 mL), 160 mL 
of a 3.33 M solution of NaOH in methanol was added into a round bottomed flask obtaining a final alkali concentration 
of 2.82 M. The mixture was stirred at room temperature, and after 14 hours TLC (petroleum ether/ethyl acetate 6:4) 
revealed the absence of starting material (1). The solvents were then removed under reduced pressure; the resulting 
residue was mixed with distilled water (200 mL) and extracted with diethyl ether (3x100 mL) in order to remove any 
traces of unreacted ester starting material (1). The aqueous phase was then acidified with HCl 2M to pH 2 and 
extracted with dichloromethane (3x100 mL). The combined organic layers were dried over MgSO4, filtered, and the 
solvent removed under reduced pressure to give (2) as an oil (yield 6.0 g, 84%). 1H NMR (400 MHz, CDCl3, δ, ppm): 
7.35 (s, 2H, CHaromatic), 6-14-6.03 (m, 3Hallyl), 5.47-5.16 (m, 6Hallyl), 4.66-4.62 (m, 6H, OCH2) 13C NMR (101 MHz, CDCl3, 
δ, ppm): 171.4, 152.4, 142.0, 134.3, 133.1, 123.9.1, 118.0, 117.8, 108.9, 74.2, 70.0. ESI-TOF mass spectrometry: 
expected m/z [M-H+] 291.32, found 291.41. FT-IR: 1687 cm-1 C=O). 
3,4,5-tris(allyloxy)benzoyl chloride (3). Compound (2) (1.0 g, 3.4 mmol, 1.0 eq.) was dissolved in anhydrous 
dichloromethane (50 mL). Anhydrous DMF catalyst (2 drops) and oxalyl chloride (0.66 g, 5.2 mmol, 1.5 eq.) were 
added to the solution under N2 atmosphere via syringe. The mixture was stirred at room temperature for 1 h, until 
evolution of gas could no longer be observed. The volatiles were then removed under reduced pressure, and the 
residue was redissolved in dichloromethane and the solvent removed under reduced pressure. This procedure was 
repeated several times in order to remove all traces of residual oxalyl chloride and provide analytically pure (3) as 
orange viscous oil, which was used for next step without further purification. Yield: 1.0 g, quant. 1H NMR (400 MHz, 
CDCl3, δ, ppm): 7.35 (s, 2H, CHaromatic), 6.08-5.97 (m, 3Hallyl), 5.44-5.15 (m, 6Hallyl), 4.66-4.58 (m, 6H, OCH2). 13C NMR 
(101 MHz, CDCl3, δ, ppm): 167.6, 152.4, 144.3, 133.9, 132.6, 127.7.1, 118.4, 118.2, 110.9, 74.3, 70.2. FT-IR: 1749 cm-1 
( C=O). 
mPEG2k triallyl ether (4). Methoxypolyethylene glycol amine 2.0 kDa (1.5 g, 0.75 mmol) was dissolved in toluene (50 
mL) and solvent was then removed under reduced pressure. This procedure was repeated five times, to remove traces 
of water from the PEG starting material, before starting the reaction. Compound (3) (1.00 g, 3.20 mmol, 4.2 eq.), 
methoxypolyethylene glycol amine 2,0 kDa (1.5 g, 0.75 mmol, 1.0 eq.) and anhydrous triethylamine (0.70 g, 6.9 mmol, 
9.2 eq.) were dissolved in anhydrous dichloromethane (50 mL) under inert atmosphere. The mixture was stirred at 
room temperature overnight, after which time 1H NMR analysis showed that the reaction was complete (aromatics 
signals shifted from 7.35 to 7.04 ppm). The solvent was then removed under reduced pressure, and the resulting 
residue suspended in 60 mL of water. Insoluble starting material (3) and potential compounds derived from it were 
removed by filtration, and the aqueous solution was extracted with Et2O (3x100 mL) to remove triethylamine and 
other non-water soluble impurities, and finally with dichloromethane (3x100 mL). Removal of the solvent from the 
combined organic layers gave (4) as a waxy solid (yield: 1.6 g, 92%). 1H NMR (400 MHz, CDCl3, δ, ppm): 7.04 (s, 2H, 
CHaromatic), 6.75 (bs, 1H, NHCO) 6.08-5.97 (m, 3Hallyl), 5.44-5.15 (m, 6Hallyl), 4.64-4.57 (m, 6H, OCH2), 3.64-3.50 (s, 194H, 
OCH2 of PEG), 3.37 (s, 3H, OCH3 of PEG). 
TriaminoPEG2k (5). mPEG2k triallyl ether (4) (1.6 g, 0.69 mmol, 1.0 eq.), cysteamine hydrochloride (0.90 g, 12 mmol, 16 
eq.) and 2,2-dimethoxy-2-phenylacetophenone (DPAP) (0.060 g, 0.23 mmol, 0.3 eq.) were dissolved in methanol (5 
mL). The mixture was then irradiated using a 36 Watt UV Lamp equipped with 4 X 9 W Light bulbs at 365 nm for 3 
hours, until allyl signals could no longer be detected by 1H NMR. Methanol was then evaporated under reduced 
pressure and the resulting residue was suspended in water. The mixture was extracted with ethyl acetate in order to 
remove traces of DPAP and corresponding decomposition products. After saturation with NaCl the aqueous phase 
was extracted with isopropanol:dichloromethane 3:1 vol:vol. Solvent removal under reduced pressure from the 
combined organic layers provided (5) as solid (1.5 g, 76%). 1H NMR (400 MHz, CD3OD, δ, ppm): 7.24 (s, 2H, CHaromatic), 
4.22 (t, J = 6.0 Hz, 4H, OCH2CH2CH2S), 4.14 (t, J = 5.8 Hz, 2H, OCH2CH2CH2S), 3.85-3.50 (s, 236H, OCH2 of PEG), 3.35 (s, 
3H, OCH3 of methoxy PEG), 3.20 (t, J = 6.7 Hz, 6H, CH2N), 2.90-2.78 (m, 12H, CH2S), 2.18 (m, 4H, OCH2CH2CH2S), 1.97 
(m, 2H, OCH2CH2CH2S). 
γ-Benzyl-L-glutamate N-carboxyanhydride (NCA). L-Glutamic acid γ-benzyl ester (13.7 g, 57.8 mmol) was added to a dry 
round bottomed flask. Anhydrous THF (200 mL) and triphosgene (6.8 g, 23 mmol) were then added under nitrogen 
atmosphere. The mixture was heated at 50 ºC under stirring. The reaction mixture turned clear in about 1 h. The 
solution was then cooled down to room temperature and bubbled with nitrogen for 2 h to remove traces of gaseous 
co-products (during this process the outlet was connected to a NaOHaq trap). The solution was then concentrated 
under vacuum to a ~ 10 mL volume, precipitated with petroleum ether, filtered, washed with petroleum ether and 
recrystallised from THF:petroleum ether 1:1 (v/v) at 0 ºC to give the desired product as crystalline solid (5.2 g, 35%). 
The residual mother liquor contained more γ-benzyl-L-glutamate N-carboxyanhydride, which however did not 
crystallise under these conditions.  1H NMR (400 MHz, CDCl3, δ, ppm): 7.40-7.31 (m, 5H, CHaromatic), 6.59 (s, 1H, NH), 
5.13 (s, 2H, CH2O), 4.38 (ddd, J = 6.5, 5.4, 0.8 Hz, 1H, CHNH), 2.59 (t, J = 6.9 Hz, 2H, CH2), 2.31-2.06 (m, 2H, CH2). 13C 
NMR (101 MHz, CDCl3, δ, ppm): 172.5, 169.5, 151.9, 135.3, 128.8, 128.7, 128.5, 67.2, 57.0, 30.0, 27.0. FT-IR: 1651, 
1737, 1790, 1856 and 1965 cm-1. 
mPEG2k-poly(glutamic acid) copolymers: typical polymerisation conditions and hydrolysis of benzyl ester repeating units. 
TriaminoPEG2k initiator (5) (50 mg, 0.019 mmol) or commercially available methoxypolyethyleneglycol amine 2.0 kDa 
(50 mg, 0.025 mmol) were dissolved in dry THF (50 mL) in a round bottom flask and cooled to 0 ºC. γ-Benzyl-L-
glutamate NCA (628 mg, 2.39 mmol), (250 mg, 0.940 mmol), (333 mg, 1.25 mmol), or (83 mg, 0.32 mmol) to form 
mPEG2k-mik-(GA30)3, mPEG2k-mik-(GA10)3, mPEG2k-lin-GA30, and mPEG2k-lin-GA10 copolymers, respectively was 
dissolved in anhydrous THF (100 mL), cooled to 0 ºC and added to the solution containing the amino-PEG initiator. 
The mixture was stirred in a water ice bath at 0ºC under inert atmosphere. After 5 days at 0ºC the conversion was 
found to be ~ 70% as judged by 1H NMR analysis. 6, 2.35, 2.35, or 0.79 mL of 1.0 M NaOH aqueous solution to hydrolyse 
benzyl ester repeating units in mPEG2k-mik-(GA30)3, mPEG2k-mik-(GA10)3, mPEG2k-lin-GA30, and mPEG2k-lin-GA10 
copolymers respectively, (2.5 equiv. of NaOH per benzyl group) were then slowly added under vigorous stirring. The 
reaction was left to stir for 2 days at room temperature, then the solvents were removed under reduced pressure. 
The residue was dissolved in distilled water (50 mL) and the resulting solution was dialysed (MWCO 1 kDa for linear 
mPEG2k-lin-GA10 copolymers or 3 kDa for mPEG2k-lin-GA30, mPEG2k-mik-(GA10)3 and mPEG2k-mik-(GA30)3 copolymers). 
The solution was then freeze-dried and analysed by 1H NMR in D2O and Size Exclusion Chromatography (SEC) using 
aqueous 0.10 M NaNO3, 0.02 NaN3, pH 1038 as the mobile phase. Mn,NMR was calculated by comparing the integrals of 
the OCH2 protons of the mPEG2k block at 3.6 ppm, and those relative to the polyGA block (see Fig. 1 for peaks 
assignment). 
mPEG2k-mik-(GA30)3 yield: 178 mg, 60%. 1H NMR (400 MHz, D2O, δ, ppm): 7.15 (s, 2H, CHaromatic), 4.38-3.99 (m, 88H, 
HNCHCO and 6H, CH2NH), 3.70-3.47 (s, 158H, OCH2 of PEG), 3.3 (s, 3H, OCH3 of PEG), 3.18-2.90 (m, 12H, CH2SCH2), 
2.4-1.6 (m, 607H, CH2CH2COOH and 6H, CH2). Mn,NMR  = 15.5 kDa, MnSEC = 7.0 kDa, Đ = 1.27.  
mPEG2k-mik-(GA10)3 yield: 120 mg, 90%. 1H NMR (400 MHz, D2O, δ, ppm): 7.15 (s, 2H, CHaromatic), 4.38-3.99 (m, 31H, 
HNCHCO and 6H, CH2NH), 3.70-3.47 (s, 180H, OCH2 of PEG), 3.3 (s, 3H, CH3O of PEG), 3.18-2.90 (m, 12H, CH2SCH2), 
2.4-1.6 (m, 126H, CH2CH2COOH and 6H, CH2NH). Mn,NMR = 7.2 kDa, Mn,SEC = 4.7 kDa, Đ = 1.28.  
mPEG2k-lin-GA30 yield: 140 mg, 80%. 1H NMR (400 MHz, D2O, δ, ppm): 4.38-3.99 (m, 39H, HNCHCO), 3.70-3.47 (s, 
165H, OCH2 of PEG), 3.3 (s, 3H, CH3O of PEG), 2.4-1.6 (m, 161H, CH2CH2COOH). Mn,NMR = 7.7 kDa, Mn,SEC = 1.9 kDa, Đ = 
1.26.  
mPEG2k-lin-GA10 yield: 71 mg, 81%. 1H NMR (400 MHz, D2O, δ, ppm): 4.38-3.99 (m, 14H, HNCHCO), 3.70-3.47 (s, 
1770H, OCH2 of PEG), 3.3 (s, 3H, CH3O of PEG), 2.4-1.6 (m, 77H, CH2CH2COOH). Mn,NMR = 3.9 kDa, Mn,SEC = 2.2 kDa, Đ = 
1.24. 
Preparation of polymer-protein nanocomplexes. Association was assessed at different polymer-protein mixing ratios (r 
= 0.1, 0.25, 0.5, 1.0, 1.5, 2.0 and 2.5) where r was the ratio between the number of glutamic acid residues present in 
the copolymer and the number of lysine and arginine residues in lysozyme. Polymer and protein stock solutions were 
prepared by separately dissolving them in phosphate buffer (PB, 10 mM, pH 7.4; Na2HPO4 8.1 mM, NaH2PO4·2H2O 
1.47 mM) at a concentration of 10 mg mL-1 and 14.5 mg mL-1, respectively, and appropriate aliquots mixed in order 
to achieve the desired r values. Protein concentration was kept constant at 300 µg mL-1 in all mixing ratios, unless 
otherwise stated. The mixtures were stored overnight at room temperature prior to further characterisation.  
Agarose gel electrophoresis. Polymer-protein complexes were prepared as described above at the same mixing ratios. 
Protein concentration was kept constant (300 µg mL-1). 50 µL of complexes solution were loaded onto 1% (w/v) 
agarose gel with 25 µL of solution of 25 mg mL-1 ethidium bromide and the electrophoresis was ran with TRIS-acetate-
EDTA (TAE) buffer at 100 mA for 2 hours. The resulting gel was stained with Coomassie blue and visualised on an 
ultraviolet transilluminator. Free lysozyme and free polymers were used as controls.  
To perform agarose gel electrophoresis with complexes at acid pH, polymer-protein associations were prepared as 
described before using a phosphate buffer at pH 2 (10 mM, pH 2.0). The procedure was the same as described before.  
Nanoparticle Tracking Analysis (NTA). The hydrodynamic diameter of complexes was measured by NTA using a 
Nanosight LM14. All measurements were performed at 25 °C. NTA 2.0 Build 127 software was used for data 
acquisition and analysis. The samples were measured for 80 s. Mean size (±SD) values correspond to the arithmetic 
values calculated for all the particles analysed by the software. Polymer-protein nanocomplexes were prepared as 
described before using ratios of 1.0 and 2.5, in phosphate buffer, 10 mM, pH 7.4. Protein concentration was kept 
constant (70 µg mL-1) for all measurements. Free protein and polymers were used as controls. 
Intrinsic fluorescence spectroscopy. Protein tryptophan fluorescence spectra were measured using a Cary Eclipse 
Fluorescence Spectrophotometer. The excitation wavelength was 280 nm. Slits were 5.0 and 10.0 nm for excitation 
and emission, respectively. Polymer-protein nanocomplexes were prepared as described before using a charge ratio 
of 2.5. Protein concentration was kept constant (70 µg mL-1). 
Circular dichroism spectroscopy. CD spectra were recorded on an Applied Photo-physics Chirascan circular dichroism 
spectropolarimeter using a 1 mm path length quartz cuvette. CD measurements were performed at 25°C over a range 
of 180-250 nm using a response time of 1 s, 1 nm pitch and 0.5 nm bandwidth. The recorded spectra represent a 
smoothed average of three scans, zero-corrected at 250 nm and normalized (Molar ellipticity θ is quoted in 105 deg 
cm2 dmol−1). The absorbance of the buffer was subtracted from the recorded spectra. Polymer-protein complexes 
were prepared as described before using a charge ratio of 0.1, 1 and 2.5. Protein concentration was kept constant (37 
µg mL-1). 
Lysozyme enzymatic activity assay. A turbidimetric enzymatic assay was performed by measuring the decrease in 
optical density of an aqueous suspension of Micrococcus lysodeikticus lyophilised cells, a natural substrate for 
lysozyme, in PB. Polymer-protein complexes were prepared as described before at ratios 0.1, 0.5, 1.0 and 2.5. 
Lysozyme concentration was kept constant (37 µg mL-1). PB (20 mL) solution was added to 10 mg of lyophilised cells. 
300 µL of this substrate suspension were added to 150 µL of nanocomplexes solution and the decrease in optical 
density at λ = 460 nm was measured as a function of time. Free polymers and free lysozyme were used as controls at 
the same concentration as in the samples. All kinetics experiments were carried out in triplicate.  
To recover lysozyme from the nanocomplexes, 480 μg of poly(allyl amine) (Mw ~17 kDa, 20 wt. % solution in H2O) 
were added to 2 mL of the nanocomplex suspension and the resulting solution mixture was maintained under very 
gentle agitation for 1 h at room temperature. Lysozyme activity of the resulting solution was then measured as 
described above. 
 
Results and discussion 
Synthesis of miktoarm and linear mPEG2k-poly(glutamic acid) copolymers 
In this work, we synthesised two novel A-B3 miktoarm star polymers consisting of one 2.0 kDa monomethoxy 
polyethylene glycol (mPEG2k) arm (A) and three poly(glutamic acid) poly(GA) branches (B) of variable chain length. 
Glutamic acid repeating units were utilised here as potential binding sites for the complexation of positively charged 
aminoacids in protein structure.  
 
Formation of polymer-protein complexes was expected to occur through electrostatic interactions, and be especially 
favoured at a pH window between the pKa of carboxylic groups of poly(glutamic acid) and the pI of the selected 
protein. In this work the length of the hydrophilic mPEG2k A block was kept constant and that of protein-binding 
polyGA arms was systematically varied. Methyl 3,4,5-trihydroxybenzoate (gallic acid methyl ester) was used as the 
starting point to generate the core of the miktoarm polymers synthesised. Reaction with allyl bromide using 
potassium carbonate as a base afforded the triallyl ether (1)39 in virtually quantitative yield (Scheme 1).
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Scheme 1. Reactions and conditions. a) allyl bromide, K2CO3, acetonitrile, heated to reflux, 3 h; b) NaOH, MeOH/CH2Cl2, 14 h; c) oxalyl 
chloride, DMF, CH2Cl2, 1 h; d) methoxypolyethylene glycol amine 2.0 kDa, triethylamine, CH2Cl2, overnight; e) cysteamine hydrochloride, 
DPAP, MeOH, UV, 3 h; f) and g) 1) γ-benzyl-L-glutamate NCA, THF, 0 ºC, 5 days and 2) NaOH, H2O/THF, 2 days.      
 
Hydrolysis of (1) with methanolic NaOH gave the acid (2) which was then converted in its correspondent acid chloride 
(3) with oxalyl chloride, using DMF as the catalyst. Whilst both 1H and 13C NMR analyses were found not suitable to 
differentiate between (2) and (3), FT-IR showed the disappearance of the band at 1687 cm-1 for the acid moiety of 
(2), and the appearance of a new band at 1749 cm-1 of the C=O stretching of the acid chloride group of (3). The latter 
was then reacted with methoxypolyethylene glycol amine 2.0 kDa in anhydrous dichloromethane using triethylamine 
as the acid scavenger (4). Thiol-ene40 addition in the presence of cysteamine hydrochloride and 2,2-dimethoxy-2-
phenylacetophenone (DPAP) photoinitiator under irradiation at λ=365 nm in methanol for 3 hours gave the desired 
mPEG2k-triamino initiator (5). Quantitative conversion of triallyl mPEG2k (4) into (5) was achieved after careful 
optimisation of the thiol-ene reaction conditions, especially in terms of amount of solvent required, 
alkyne:photoinitiator molar ratio, and reaction time. 
Polymerisation of α-amino acid-N-carboxyanhydrides (NCAs) has emerged in recent years as one of the most efficient 
and versatile routes to synthetic homopolypeptides. The polymerisation requires a nucleophilic initiator, typically a 
primary amine and proceeds by sequential nucleophilic ring-opening of the monomer(s) NCA ring, affording well-
defined polymers with low polydispersities provided that side reactions are minimised.41 Loss of control can occur via 
several mechanisms. For example, dry conditions are essential as water can act as an initiator and start the 
polymerisation process. Habraken et al. showed that NCA polymerisation at 0ºC leads to poly(glutamic acid) with very 
high fidelity in amino-end groups required to achieve control over the polymerisation process, leading to well-defined 
polymers with low polydispersities. However, at higher temperatures pyroglutamates end-groups were generated, 
leading to unwanted chain termination and broader molecular weight distributions.42  
In the present study, a family of mPEG2k-poly(GA) copolymers with linear and miktoarm macromolecular structures 
was prepared from initiators (5) and mPEG2kNH2, respectively. The number of glutamic acid (GA) monomer units in B 
block arms were either 10 or 30 in both linear and miktoarm polymers (Table 1). 
 
Table 1. Composition, architecture, Mn, and polydispersity of mPEG2k-polyGA copolymers prepared in this study. 
Polymer Architecture 
Mn, Theo 
(kDa)a 
Mn,NMR 
(kDa)b 
Mn,SEC 
(kDa)c 
Đ SECc 
mPEG2k-mik-(GA10)3 miktoarm 7.0 7.2 4.7 1.28 
mPEG2k-mik-(GA30)3 miktoarm 14.8 15.5 7.0 1.27 
mPEG2k-lin-GA10 linear 3.3 3.9 2.2 1.24 
mPEG2k-lin-GA30 linear 7.1 7.7 1.9 1.26 
a Calculated from [Monomer]0/[Initiator]0 and conversion values for each polymerisation run; b Copolymers composition estimated by 1H 
NMR in D2O.  c Determined by SEC in aqueous 0.10 M NaNO3, 0.02 (w/v) NaN3, pH 10.0 as the mobile phase,38 in a system calibrated with 
0.2-130 kDa PEO standards. 
Linear mPEG2k-lin-GA10 and mPEG2k-lin-GA30 copolymers were synthesised using commercially available monoamino 
mPEG2k (2.0 kDa) as the polymerisation initiator, whilst for miktoarm mPEG2k-mik-poly(GA)3 copolymers a tri-
functional initiator (5) was required. All polymerisation reactions were carried out at 0°C and monitored by 1H NMR, 
by following the disappearance of the α-CH proton signal of the NCA monomer at 4.4 ppm. The polymerisations were 
stopped at ~70% conversion, which generally occurred within 5 days.  
Treatment of the reaction crude product with NaOHaq afforded the required mPEG2k-polyGA copolymers, which were 
purified by dialysis against deionised water (MWCO 1-3 kDa). 
A typical 1H NMR spectrum of a mPEG2k-poly(GA) copolymer is shown in Fig. 1. Mn,NMR were calculated by comparing 
the integral of the ethylene repeating units of mPEG2k with that of the CHN groups in the glutamic acid repeating 
units, and were found to be in good agreement with the theoretical ones, calculated from the initial (mPEG 2k 
initiator):(glutamic acid N-carboxyanhydride monomer) molar ratios and the final monomer conversions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 1H NMR spectrum of miktoarm mPEG2k-mik-(GA10)3 in D2O. 
1H NMR confirmed that the Mn,NMR of all copolymers was in line with the expected theoretical values (Table 1). SEC 
analysis using SEC aqueous 0.10 M NaNO3, 0.02 (w/v) NaN3, pH 1038  showed a lower average molecular mass Mn,SEC  
which could be ascribed to the difference in relative hydrodynamic diameter between mPEG2k- polyGA and mPEG 
narrow standards used to calibrate the SEC.  
 
Polymer-protein complexes characterisation 
Next, the ability of mPEG2k-polyGA copolymers to complex model protein, lysozyme, was assessed. Hen egg-white 
lysozyme is a 129 aminoacid, 14.3 kDa protein43 with isoelectric point at pH 11.3,44 with 6 lysine and 11 arginine 
residues45 exposed at the surface of the protein. This enzyme has a net positive charge (+7.5) at physiological pH46 
which potentially could allow its complexation with polyanionic macromolecules.  
 
In this study polymer:protein complexes were studied by incubating mPEG2k-polyGA copolymers and lysozyme in 10 
mM phosphate buffer, pH 7.4 or pH 2.0. Association was assessed in the 0.1-2.5 range of mixing ratios r, defined as 
the relative molar charge ratio between the number of glutamic acid monomer units in mPEG2k-polyGA copolymers 
(mostly negatively charged at pH 7.4), and the number of lysine and arginine residues in the lysozyme (positively 
charged at both pH 7.4 and 2.0). 
Poly(glutamic acid) possesses mostly a α-helix conformation (~ 3.6 residues per turn) at pH < 5, in aqueous media, 
whilst at pH > 6 it exhibits a random coil conformation.47 This coil-to-helix conformation transition depends on 
different factors, including pH, chain length, concentration and temperature.48, 49 At pH 7.4 poly(GA) is expected to 
assume mostly a random coil conformation due to Coulombic repulsion between ionised glutamate sidechains,49 thus 
potentially further favouring protein complexation. The protein concentration was kept constant (300 µg mL-1), whilst 
the polymer concentration was varied to obtain the desired r values.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 Electrophoretic mobility at pH 2.0 (A) and pH 7.4 (B) of lysozyme from protein complexes with linear mPEG2k-lin-GA10 and 
mPEG2k-lin-GA30, and miktoarm mPEG2k-mik-(GA10)3 and mPEG2k-mik-(GA30)3-derived complexes in a 1% agarose gel, run 2 h at 100 
mA in Tris-Acetate-EDTA buffer.  
 
Protein complexation was first assessed by agarose gel electrophoresis in an electrophoretic mobility shift assay (Fig. 
2). The efficiency of protein-(mPEG2k-polyGA) complexation was found to be pH-dependent, with no complexation 
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observed at pH 2.0 (Fig. 2A), where carboxylic groups of the glutamic acid repeating units exist in their protonated 
uncharged form, and are hence unable to engage with positively charged Lys and Arg protein residues. Taken together 
with evidence of protein-(mPEG2k-polyGA) complexation under pH 7.4 conditions (Fig. 2B) these results further 
confirm that the complexation process was indeed driven by ionic interactions between the species. The pH 7.4 gels 
followed a general pattern, where bands were observed at low r ratios, indicating the presence of either weakly 
complexed, or free protein. As the amount of copolymer increased at higher r ratios, the free protein bands gradually 
became dimmer, indicating greater level of complexation with the copolymer, until they eventually disappear. At 
higher r ratios increased staining could be seen in the wells, which was suggestive of the presence of large and/or of 
neutral or negatively charged complexes which prevented their migration out of the well.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3 Particle size distribution of mPEG2k-lin-GA10, mPEG2k-lin-GA30, mPEG2k-mik-(GA10)3 and mPEG2k-mik-(GA30)3-derived 
complexes with lysozyme at charge ratio 1.0 (A) and 2.5 (B). DH is the average hydrodynamic diameter ± SD of polymer-protein 
nanocomplexes as assessed by nanoparticle tracking analysis (NTA).  
These results suggested a dependence of protein complexation on the molecular composition and architecture of the 
complexing copolymer. Low level of complexation was found for linear mPEG2k-lin-GA10 which was not significantly 
improved by the use of a miktoarm mPEG2k-mik-(GA10)3 copolymer, containing three arms of GA10. Intriguingly, the 
same number of GA monomeric units (30) but arranged in a linear chain of mPEG2k-lin-GA30 copolymer produced a 
superior complexation whereby, from approximately r ≥ 1.0, no free protein could be observed in the gel. Further 
increase in the number of GA30 branches in mPEG2k-mik-(GA30)3 miktoarm resulted in a gel pattern similar to that 
observed for mPEG2k-lin-GA30. 
The particle size of lysozyme-(mPEG2k-polyGA) complexes at 1.0 and 2.5 ratios were analysed by nanoparticle tracking 
analysis (NTA). In the present study, NTA was found to be superior to dynamic light scattering (DLS) to estimate the 
size of relatively polydisperse samples of polymer:protein complexes in suspension, as reported previously.50 For r = 
2.5 all lysozyme-(mPEG2k-polyGA) complexes were found to possess average diameter in the 50-200 nm range (Fig. 3) 
with relatively broad particle size distribution.  At r = 1.0 mPEG2k-lin-GA10, mPEG2k-lin-GA30 and mPEG2k-mik-(GA30)3 
copolymers showed a hydrodynamic diameter between 50 and 150 nm whilst the presence of larger polymer-protein 
complexes was detected with mPEG2k-mik-(GA10)3. Neither unmodified lysozyme nor free mPEG2k-polyGA copolymers 
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could be detected by NTA, further confirming that the sizes analysed were polymer:protein complexes. TEM images 
of representative lysozyme-(mPEG2k-lin-GA30) complexes at r = 2.5 (ESI Fig. S22) illustrate the presence of numerous 
complexes in the size range of 30-50 nm, as well as existence of some larger species, probably aggregates. 
Taken together, agarose gel electrophoresis, particle size analysis and TEM suggest that binding of the copolymers to 
lysozyme initiated ‘controlled assembly’ into complexes made of multiple molecules of lysozyme and copolymers. 
This agrees with previous work where mPEG12k-lin-Asp18 copolymers were utilised to form stable lysozyme complexes 
consisting of 36 and 42 molecules of lysozyme and mPEG-b-poly(Asp), respectively.12 One could propose that the 
presence of PEG2k may prevent higher order aggregation of protein-(mPEG2k-b-polyGA) complexes when their overall 
charge is close to neutral, as previously suggested for mPEG5k–b-poly(N,N-dimethylaminoethyl methacrylate) (PAMA) 
copolymer when complexing L-asparaginase.51   
Current literature indicates that protein binding efficiency and size of the resulting ionic complexes depend on a 
complex interplay between a number of parameters, including size and charge density of both polymers and proteins, 
pH, ionic strength, [polymer]:[protein] molar ratio, and, for PEG-containing block copolymers, the relative size of PEG 
and polyionic blocks. Under the complexation conditions of the present work (pH > 6), random coil conformation of 
polyglutamic acid chain would be expected, as discussed above, to allow for its relative conformational freedom in 
interaction with surface groups of lysozyme, however it is not clear at this point if the chain would have such a 
flexibility to as to ‘wrap around’ the protein to form multiple interactive contacts.52 The superior complexation of 
linear GA30 relative to both linear polyGA10 and miktoarm poly(GA10)3 copolymers might be pointing to such a 
‘wrapping’ and formation of multiple contacts as the chain length is increased. Positively charged aminoacid residues 
of lysozyme appear distributed throughout the protein surface53 rather than creating ‘charged patches’; this may 
favour creation of interactive contacts with polyGA30 linear chain of mPEG2k-lin-GA30 rather than ‘grouped’ anion 
charges in miktoarm mPEG2k-mik-(GA10)3.  
Lysozyme conformation in protein-polymer complexes: intrinsic fluorescence studies 
Protein intrinsic fluorescence studies were carried out to investigate whether the conformation of lysozyme was 
affected by polymer complexation. Selected fluorescence spectra of polymer-protein complexes at a 2.5 ratio are 
shown in Fig. 4. Spectra are dominated by tryptophan fluorescence due to the presence of six tryptophan residues - 
Trp-28, Trp-62, Trp-63, Trp-108, Trp-111 and Trp-123 - within the lysozyme structure. The maximum of fluorescence 
emission λmax of tryptophan-containing native proteins typically falls in the 308-350 nm range, the exact position 
depending on burial of individual tryptophan residues within protein domains. Protein unfolding typically results in 
exposure of tryptophan residues to more polar and solvent exposed local environments, leading to a red shift of 
fluorescence λmax, typically in the 345-355 nm range.54 At 25 °C native lysozyme in 10 mM phosphate buffer, pH 7.4 
showed a maximum emission at λ=344 nm. However, upon heating at 95 °C for 120 min, λmax shifted to 350 nm. This 
bathochromic shift has been observed before, and was ascribed to unfolding of lysozyme.55, 56 For (mPEG2k-polyGA)-
lysozyme complexes, a slight hypsochromic (blue) shift of λmax was observed, irrespective of the polymer 
macromolecular architecture and length of polyGA protein-binding arm(s), suggesting that upon complexation 
lysozyme did not unfold (Fig. 4). This blue shift may indicate that within these complexes tryptophan residues were 
actually exposed to a more apolar environment.56 
 
Circular dichroism experiments on polyGA-lysozyme-(mPEG2k-polyGA) complexes (ESI Fig. S21) proved less 
informative due to significant overlap between the spectra of the poly(glutamic acid) moiety and lysozyme. Although 
not conclusive, the data however indicated that, at least for low polymer:protein ratios, no detectable protein 
unfolding occurred, which is in agreement with the intrinsic tryptophan fluorescence results. 
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Fig. 4 Tryptophan fluorescence spectra of lysozyme after complexation with linear mPEG2k-lin-GA10 and mPEG2k-lin-GA30, and 
miktoarm mPEG2k-mik-(GA10)3 and mPEG2k-mik-(GA30)3 copolymers at charge ratio 2.5 in 10 mM phosphate buffer pH 7.4. Polymer-
protein complexes (blue), native lysozyme (red) and denatured protein (black). All spectra recorded at room temperature.  
Lysozyme activity assay 
Lysozyme exerts its antimicrobial activity by selectively cleaving β-1,4-glycosidic bonds between N-acetylmuramic 
acid and N-acetylglucosamine, found in bacterial cell walls.57 The effect of protein complexation on the residual 
enzymatic activity of lysozyme at various protein:polymer ratios was assessed using Micrococcus lisodeikticus 
lyophilised cell walls at the substrate. For all mPEG2k-polyGA investigated, lytic activity decreased after polymer-
protein complexation (Fig. 5) suggesting that enzyme was located within the interior of these assemblies, where the 
enzyme active centre was less accessible.58 A decrease in lytic activity due to protein denaturation,59 or changes in its 
secondary structure seemed unlikely, given the results from our intrinsic fluorescence studies. Similar decrease in 
lysozyme enzymatic activity was seen in complexation with polyanionic poly(acrylic acid).60  
A more pronounced decrease in lysozyme activity at higher polymer:protein ratios suggests an increased 
complexation level (Fig. 5), which can supported by gel electrophoresis data showing more pronounced protein 
sequestration at higher polymer:protein ratios (Fig. 2B). (mPEG2k-lin-GA30)-lysozyme complexes showed the highest 
reduction in enzymatic activity, again indicating the importance of copolymer architecture and the length of protein-
binding polyGA moiety on sheltering of the enzyme catalytic pocket.  
 
For comparative purposes, irreversible covalent PEGylation of lysozyme was carried out using methoxy PEG2k 
succinimidyl carbonate to generate conjugates with average number of mPEG chains ranging from 5.2-6.3 per 
lysozyme macromolecule. These conjugates were found to possess minimal or no residual enzymatic activity, as 
confirmed by Micrococcus lisodeikticus turbidimetric assay (see ESI Fig. S24). This is in agreement with previous work, 
which indicated that some lysine residues – e.g. Lys97 - are located in a region responsible for substrate specificity.61 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5 A. Lysozyme enzymatic activity of linear mPEG2k-lin-GA10 and mPEG2k-lin-GA30, and miktoarm mPEG2k-mik-(GA10)3 and 
mPEG2k-mik-(GA30)3-derived complexes (n=3).  Free protein (red), free polymer (black), and 0.1 (green), 0.5 (orange), 1.0 (grey) and 
2.5 (pink) polymer:protein charge ratio r. OD460nm represents the optical density of the samples at λ=460 nm. B. Lysozyme 
enzymatic activity of selected complexes at polymer-protein charge ratio of 2.5 – with either linear mPEG2k-lin-GA30, and miktoarm 
mPEG2k-mik-(GA10)3 – before and after polymer decomplexation by addition of poly(allyl amine) (240 µg mL-1, 4.2 mM of protonable 
amino groups).  
 
By contrast to PEG-conjugated lysozyme, full enzymatic activity was recovered upon de-complexation of lysozyme 
from the protein-(mPEG2k-polyGA) nanocomplexes by addition of 17 kDa poly(allyl amine), a known complexant for 
polyanionic polymers60 (Fig. 5B). Thus, this data confirmed that initial decrease of enzymatic activity was indeed due 
to inclusion of lysozyme within polymer nanocomplexes which limited the accessibility of its catalytic pocket, whereby  
subsequent complete recovery of activity clearly indicate that polymer  complexation induced no irreversible protein 
unfolding or denaturation confirming this advantage of the complexation approach adopted.  
 
Conclusions 
In this work a family of PEG-polyanion copolymers suitable for non-covalent and reversible complexation of proteins 
is presented. mPEG2k-poly(glutamic acid) copolymers with different architecture, linear A-B and miktoarm A-B3, and 
different length of the protein-binding arms were synthesised by NCA polymerisation, and their ability to bind model 
protein (lysozyme) was investigated.  
Electrophoresis and nanoparticle tracking analysis indicated that the length of protein-binding poly(glutamic acid) 
arms of the copolymers, as well as their macromolecular architecture had a significant effect on complexation 
efficiency, where for copolymers with the same number of glutamic acid repeating units, polymers with linear 
architecture were more efficient, than their miktoarm analogues, to complex lysozyme model protein.  
Importantly, upon polymer complexation the protein structural conformation appears to be conserved, and no 
detectable denaturation was observed. Enzymatic activity of the complexed protein was reduced, attributable to 
limited access of substrate to enzyme active site, and the extent of this reduction depends on the macromolecular 
architecture of the complexing copolymer.  
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Ultimately, this study identified a first structure-function relationship for a new family of mPEG2k-p(glutamic acid) 
polymers with various macromolecular architecture. Ongoing studies are focusing on utilising these findings to 
engineer protein therapeutics deliver systems.  
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